132 related articles for article (PubMed ID: 8299367)
1. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
Korting HC
Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
[No Abstract] [Full Text] [Related]
2. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
Korting HC
Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
[No Abstract] [Full Text] [Related]
3. Side effects of topical glucocorticoids.
Mills CM; Marks R
Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
[No Abstract] [Full Text] [Related]
4. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
5. Early detection of glucocorticoid-specific epidermal alterations using skin surface microscopy.
Schulz H; Nietsch KH; Höhler T
Curr Probl Dermatol; 1993; 21():132-9. PubMed ID: 8299366
[No Abstract] [Full Text] [Related]
6. Local tolerability of topically applied methylprednisolone aceponate.
Kecskés A; Jahn P; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
[No Abstract] [Full Text] [Related]
7. Response of segmental vitiligo to 0.05% clobetasol propionate cream.
Khalid M; Mujtaba G
Int J Dermatol; 1998 Sep; 37(9):705-8. PubMed ID: 9762827
[No Abstract] [Full Text] [Related]
8. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
[TBL] [Abstract][Full Text] [Related]
9. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
Kerscher MJ; Korting HC
Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
[TBL] [Abstract][Full Text] [Related]
10. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
11. Nonpigmenting solitary fixed drug eruption after skin testing and intra-articular injection of triamcinolone acetonide.
Sener O; Caliskaner Z; Yazicioglu K; Karaayvaz M; Ozangüç N
Ann Allergy Asthma Immunol; 2001 Mar; 86(3):335-6. PubMed ID: 11289335
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo.
Khalid M; Mujtaba G; Haroon TS
Int J Dermatol; 1995 Mar; 34(3):203-5. PubMed ID: 7751099
[No Abstract] [Full Text] [Related]
15. Suppression of induced inflammation in man.
Kerscher MJ
Curr Probl Dermatol; 1993; 21():97-106. PubMed ID: 8299382
[No Abstract] [Full Text] [Related]
16. Cutaneous adverse reactions after intra-articular injection of triamcinolone acetonide.
Ijsselmuiden OE; Knegt-Junk KJ; van Wijk RG; van Joost T
Acta Derm Venereol; 1995 Jan; 75(1):57-8. PubMed ID: 7747537
[TBL] [Abstract][Full Text] [Related]
17. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
Callender VD; Young CM; Haverstock CL; Carroll CL; Feldman SR
Cutis; 2005 Jun; 75(6):317-21. PubMed ID: 16047868
[TBL] [Abstract][Full Text] [Related]
18. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.
Blum G; Yawalkar S
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1153-6. PubMed ID: 1757607
[TBL] [Abstract][Full Text] [Related]
19. Patients preferences for different corticosteroid vehicles are highly variable.
Felix K; Unrue E; Inyang M; Cardwell LA; Oussedik E; Richardson I; Feldman SR
J Dermatolog Treat; 2020 Mar; 31(2):147-151. PubMed ID: 29770722
[No Abstract] [Full Text] [Related]
20. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
